MTFB News and Press, Motif Bio plc From 04/04/19

Shineco (NASDAQ: TYHT ) +39% . More news on: Shineco, Inc., Recro Pharma, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four iclaprim abstracts have been accepted for presentation at the upcoming 28 th European Congress o...

Proteostasis Therapeutics (NASDAQ: PTI )  -56%  on disappointing data on CF candidates. More news on: Proteostasis Therapeutics, Inc., Recro Pharma, Inc., Motif Bio plc, Stocks on the move, Read more ...

Conatus Pharmaceuticals (NASDAQ: CNAT )  -55%  after emricasan flunks late-stage NASH study More news on: Conatus Pharmaceuticals Inc., Superconductor Technologies Inc., Motif Bio plc, Stocks on the move, Read more ...

March 21, 2019 Palm Beach, FL – March 21, 2019 – A recent article in a medical device industry periodical, INN, said that: “2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the market...

Gainers:  Estre Ambiental (NASDAQ: ESTR ) +81% . Motif Bio plc (NASDAQ: MTFB ) +71% . Nevro (NYSE: NVRO ) +33% . Electrameccanica Vehicles (NASDAQ: SOLO ) +32% . Dragon Victory International (NASDAQ: LYL ) +21% . Fibrocell Science (NASDAQ: FCSC ) +18% . Amira Nature Foods (NYSE:...

Motif Bio plc (NASDAQ: MTFB ) +55%  on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...

The FDA has granted Motif Bio's (NASDAQ: MTFB ) request for a Type A meeting to discuss the points raised in the Complete Response Letter related to the NDA for iclaprim for the treatment of acute bacterial skin and skin structure infections. More news on: Motif Bio plc, Motif Bio p...

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type A me...

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard C. E. Morgan has tendered his resignation as Non-executive Chairman and is stepping down from ...